AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer
Alexandra van den Broek talks to ecancer.tv about research indicating that age and BRCA status can be used as predictors of contralateral breast cancer risk. This small scale study revealed that patients diagnosed with first case of breast cancer who are under the age of 41 or diagnosed with triple negative breast cancer are at higher risk to develop contralateral breast cancer. If these results are validated by further studies, age status and BRCA receptor status should be included in guidelines for prophylactic measures, screening and follow up of BRCA mutation carriers.
2011 SABCS, San Antonio Breast Cancer Symposium, 6-10 December, San Antonio, USA
Influence of age and BRCA status on contralateral breast cancer risk
Alexandra van den Broek – Netherlands Cancer Institute, Amsterdam
In our study we looked at breast cancer patients and their BRCA 1 and 2 mutation status, we tested all the patients for that, and we looked then at the risk of contralateral breast cancer. We were able to define subgroups of BRCA 1 and 2 mutation carriers with an increased and decreased risk for contralateral breast cancer.
We found that patients diagnosed with the first breast cancer under the age of 41 or patients diagnosed with a triple negative first breast cancer are at a higher risk to develop contralateral breast cancer. The lowest risk groups had a cumulative ten year risk of 3.5% for the patients diagnosed between the ages of 40 to 50 with non-triple negative breast cancer. The highest risk group were the carriers diagnosed with their first breast cancer under the age of 41 and they had a 26% cumulative risk.
I have to say, this study, the numbers of carriers included in this study is still small so it should be confirmed in other studies first but, when confirmed, age criteria and maybe the receptor status could be taken into account in guidelines for prophylactic measures and screening and follow-up of BRCA1 and 2 mutation carriers.
AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer
The added value of integrative medicine
Insights into germline genetic screening of breast cancer patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Revolutionising myeloma treatment through immune profiling
Choosing Wisely for young women with breast cancer: Medical therapy
Clinical behaviour of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing
SABCS 2023: Latest breast cancer diagnostics guidelines
Genomic testing: Awareness and effective communication between healthcare professionals and patients